Show simple item record

dc.contributor.authorPercival, N
dc.contributor.authorGeorge, A
dc.contributor.authorGyertson, J
dc.contributor.authorHamill, M
dc.contributor.authorFernandes, A
dc.contributor.authorDavies, E
dc.contributor.authorRahman, N
dc.contributor.authorBanerjee, S
dc.date.accessioned2016-10-20T09:58:17Z
dc.date.issued2016-06
dc.identifier.citationBritish journal of nursing (Mark Allen Publishing), 2016, 25 (12), pp. 690 - 694
dc.identifier.issn0966-0461
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/184
dc.identifier.doi10.12968/bjon.2016.25.12.690
dc.description.abstractPurpose The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as the mainstreaming oncogenetic pathway, involving oncology health professionals are being used. The authors report on the establishment of the extended role of the clinical nurse specialist in consenting women for BRCA testing in routine gynaecology-oncology clinics using the mainstreaming model.Methods Nurses undertook generic consent training and specific counselling training for BRCA testing in the form of a series of online videos, written materials and checklists before obtaining approval to consent patients for germline BRCA1 and BRCA2 mutations.Results Between July 2013 and December 2015, 108 women with ovarian cancer were counselled and consented by nurses in the medical oncology clinics at a single centre (The Royal Marsden, UK). This represented 36% of all ovarian cancer patients offered BRCA testing in the oncology clinics at the centre. Feedback from patients and nurses was encouraging with no significant issues raised in the counselling and consenting process.Conclusion The mainstreaming model allows for greater access to BRCA testing for ovarian cancer patients, many of whom may benefit from personalised therapy (PARP inhibitors). This is the first report of oncology nurses in the BRCA testing pathway. Specialist oncology nurses trained in BRCA testing have an important role within a multidisciplinary team counselling and consenting patients to undergo BRCA testing.
dc.formatPrint
dc.format.extent690 - 694
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectOvarian Neoplasms
dc.subjectPiperazines
dc.subjectPhthalazines
dc.subjectNurse's Role
dc.subjectMutation
dc.subjectGenes, BRCA1
dc.subjectGenes, BRCA2
dc.subjectInformed Consent
dc.subjectNurse Clinicians
dc.subjectCancer Care Facilities
dc.subjectPatient Satisfaction
dc.subjectFemale
dc.subjectGenetic Testing
dc.subjectHereditary Breast and Ovarian Cancer Syndrome
dc.subjectOncology Nursing
dc.subjectPoly(ADP-ribose) Polymerase Inhibitors
dc.subjectPrecision Medicine
dc.titleThe integration of BRCA testing into oncology clinics.
dc.typeJournal Article
rioxxterms.versionofrecord10.12968/bjon.2016.25.12.690
rioxxterms.licenseref.startdate2016-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of nursing (Mark Allen Publishing)
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume25
pubs.embargo.termsNot known
icr.researchteamGenetic Susceptibilityen_US
dc.contributor.icrauthorRahman, Saberaen
dc.contributor.icrauthorBanerjee, Susanaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record